3 Evecare • Vol 11 • No. 2 • Sep–Dec 2023 Research at Himalaya Evecare forte™ Liquid in the Management of Polycystic Ovary Syndrome Aim To evaluate the efficacy and safety of Evecare forte Liquid in the management of polycystic ovary syndrome (PCOS) Materials and Methods This was an interventional, open-label clinical study that included 40 women, aged 18 to 45 years, with signs and symptoms of PCOS such as irregular menstrual cycles, weight gain, biochemical/clinical hyperandrogenemia, and hirsutism. Women with a history of PCOS, with < 8 periods in the preceding year and clinical, biochemical, and/or ultrasonographic (USG) diagnosis were also included in the study. Women with organic lesions in the reproductive tract, especially any benign or malignant growth; extensive cervical erosion; cervical polyps; endometriosis; or severe cardiac, hepatic, or mental illnesses were excluded from the study. All women who met the inclusion criteria were prescribed Evecare forte Liquid at a dosage of 20 mL, BID, for 3 months. They were followed up at months 1, 2, and 3 during the study, and their clinical signs and symptoms, USG findings, and biochemical, hematological, and hormonal parameters were monitored each time. The menstrual parameters including duration of menstrual cycle and intermenstrual interval; clinical parameters including hair loss, acne, depression, deepening An excerpt of the clinical study conducted by Ahalya S (to be published) is featured here. of voice, and hirsutism; and other parameters including BMI, waist-to-hip ratio, and skin changes such as hyperpigmentation around the face and neck were evaluated. Results The treatment with Evecare forte Liquid brought about significant improvements in menstrual parameters. There were significant reductions in the duration of menstruation (P < .035) and the intermenstrual interval (P < .0299). The hematologic parameters including hemoglobin, total blood count, differential blood count, platelet count, and erythrocyte sedimentation rate; lipid profile values; and liver function parameters were within the normal range before and after the treatment. Table 1 shows the effect of Evecare forte Liquid on hormonal parameters before and after the treatment; there was a positive effect on the hormonal levels. The testosterone level reduced significantly (P < .0063) by the end of the study. Luteinizing hormone (LH) and follicle-stimulating hormone (FSH) are the pituitary hormones that support ovulation (normal range: 5–20 IU/mL). The level of LH surges to 25 to 40 IU/mL before ovulation, and then returns to the normal level after ovulation. However, in PCOS, there may be an elevated LH to FSH ratio of 3:1. This helps in diagnosing PCOS. After the treatment with Evecare forte Liquid,
RkJQdWJsaXNoZXIy MjAwNDg=